



CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

February 15, 2025

To,
Listing Compliance Department
BSE Ltd.
P. J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 539561 / REMLIFE

Sub: Intimation of receipt of order under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to announce that the Remedium Lifecare Limited has received a multi-year supply contract from renowned pharmaceutical distribution company based in the United Kingdom. This contract encompasses the supply of a range of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals. The estimated value of the supplies scheduled from February 2025 to January 2026 alone is approximately One Hundred Eighty Two Crores Seventy Lakh Rupees only (Rs.182,70,00,000/-).

Pursuant to SEBI Circular No. CIR/CFD/CMDI4I2015 dated September 9,2015 and SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/120 of July 11,2023, Disclosure given as Annexure A.

We request you to kindly take the above on record.

Thanking you

Yours faithfully,

For Remedium Lifecare Limited

Adarsh Munjal
Whole Time Director
DIN:07304004



Encl: As above.



REMEDIIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



Annexure – A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 of July 11, 2023

| Sr. No. | Particulars | Details |
|----------------|--|--|
| a. | Name(s) of parties with whom the agreement is entered | Aster Biotech Limited, UK |
| b. | Significant terms & Condition of order(s)/contract(s) awarded in brief; | Three-year supply contract from February 2025 to January 2028. The value of supplies in the first year, that is, February 2025 to January 2026, will be about INR 182,70,00,000. |
| c. | whether order(s) /contract(s) have International entity been awarded by domestic/ international entity | International entity |
| d. | Nature of order(s)/ contract(s) | Supply of Active Pharmaceutical Ingredients (APIs), Intermediates and Specialty Chemicals |
| e. | Whether domestic or international | International |
| f. | Time period by which the order(s)/contract (s) is executed | February 2025 to January 2028 |
| g. | Board consideration or size of the order(s)/ contract(s) | In the first year, that is, February 2025 to January 2026, the value of supplies will be about INR 182,70,00,000 (One Hundred Eighty Two Crores Seventy Lakh Rupees). |
| h. | Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof | NO |
| i. | Whether the order(s)/contract(s) would fall within related party transactions ? if yes , whether the same is done at "arms length" | NO |

